Galapagos
NV announced today that its
BioFocus service division has delivered a panel of validated oncology targets
in its collaboration with Janssen Research & Development, a division of
Janssen Pharmaceutica N.V. (Janssen). Per the agreement, Janssen retains full
rights to discover, develop and commercialize novel medicines on these targets.
In January 2008, BioFocus entered into a fee-for-service
target discovery collaboration with Janssen, under which BioFocus developed
assays in cancer cells, and discovered and validated novel targets. In January
2010, BioFocus received a target acceptance payment from Janssen for
identifying and validating drug targets. BioFocus has now confirmed the
activity of a panel of targets across several key pathways in oncology, per
contractually defined criteria. BioFocus may receive success-based payments
should certain downstream criteria be reached by Janssen.
“We continue to see strong demand for our target
discovery capabilities and this collaboration is an example of how we deliver
novelty to pharmaceutical pipelines,” said Onno van de Stolpe, Chief
Executive Officer of Galapagos.
